Data from A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma

MLA

Richard F. Riedel, et al. Data from A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-Tissue Sarcoma. Mar. 2023. EBSCOhost, https://doi.org/10.1158/1078-0432.c.6529322.v1.

APA

Richard F. Riedel, Iulian Bobe, Atsushi Osada, Juneko E. Grilley Olson, Arun S. Singh, Fadi Braiteh, Warren Chow, Sanjay Goel, & Sant P. Chawla. (2023). Data from A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma. https://doi.org/10.1158/1078-0432.c.6529322.v1

Chicago

Richard F. Riedel, Iulian Bobe, Atsushi Osada, Juneko E. Grilley Olson, Arun S. Singh, Fadi Braiteh, Warren Chow, Sanjay Goel, and Sant P. Chawla. 2023. “Data from A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-Tissue Sarcoma,” March. doi:10.1158/1078-0432.c.6529322.v1.